The bill amends the Federal Food, Drug, and Cosmetic Act to give the FDA authority to authorize temporary importation of prescription drugs and to treat certain “marginally competitive” markets as de facto shortages. It pairs an expedited approval/inspection pathway for generics with a conditional, limited-duration importation mechanism intended to bring alternative supplies into the U.S. when competition is thin or unavailable.
This matters to hospitals, pharmacies, payers, generic manufacturers, and the FDA itself: it changes the legal triggers for shortage responses, sets concrete timelines (a 60-day authorization window and a 3-year importation cap), and creates a measurable test for when a market is “marginally competitive.” The bill also adds a reporting requirement so FDA will disclose how many drugs were authorized for temporary importation.
At a Glance
What It Does
The bill adds a temporary importation authority to FDA’s drug shortage statutes and creates a new ‘‘marginally competitive market’’ designation that the agency can treat as a shortage. It requires manufacturer and importer certifications, allows FDA to deny importation on safety or related grounds, and permits expedited review and inspection of generic applications tied to such markets.
Who It Affects
Pharmacies, hospitals, and clinics that depend on off-patent drugs in thin markets; generic drug manufacturers and foreign manufacturers seeking U.S. market entry; importers who meet statutory definitions; and the FDA, which must carry out expedited reviews, inspections, and new reporting obligations.
Why It Matters
The bill lowers procedural barriers to bring foreign versions of U.S. prescription drugs into the market when domestic competition is limited, while attempting to steer new generic entrants through the abbreviated new drug application (ANDA, section 505(j)). That shifts both supply-chain risk management and regulatory workload toward faster approvals and conditional importation rather than longer-term manufacturing fixes.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new temporary importation authority into FDA’s drug-shortage toolbox. When FDA determines a shortage exists or is likely, the agency must authorize importation for up to three years if five statutory conditions are met: the product is a covered prescription drug type, the same active ingredient is lawfully marketed in one or more countries on FDA’s approved list, the foreign manufacturer certifies it intends to seek approval under section 505(j), and an importer files an attestation identifying the product and source.
FDA has explicit discretion to deny importation for safety reasons, device-related safety gaps, or if foreign market approvals were rescinded over safety concerns.
The Five Things You Need to Know
If all eligibility conditions are met, FDA must authorize importation beginning no later than 60 days after the importer files the required attestation.
Temporary importation authority terminates when the shortage ends or after 3 years, whichever comes first.
The bill defines a ‘‘marginally competitive market’’ as one in which, for at least 2 consecutive months, fewer than five FDA‑approved products referencing the same listed drug were commercially available, the listed drug was approved at least 10 years earlier, and all active‑ingredient patents have expired.
In counting commercial availability, multiple approved applications held by a single entity count as only one product; a product is not commercially available if discontinued, withdrawn, or if FDA has a reasonable basis to find it not competitively relevant.
The bill amends FDA’s annual drug‑shortage report to require disclosure of the number of drugs authorized for temporary importation under the new authority.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Temporary importation authority and eligibility conditions
This provision adds subsection (h) to §506C and lists the five conditions that must be satisfied for FDA to authorize importation: the product falls within the covered prescription drug category, is lawfully marketed in one or more countries on FDA’s §802(b)(1) list, has the same active ingredient as the shortage drug, the foreign manufacturer certifies intent to seek ANDA (505(j)) approval, and an importer files an attestation identifying the drug and source. Practically, this ties importation to products already authorized abroad and to an explicit pathway toward U.S. generic approval, rather than allowing indefinite parallel importation.
Deadlines, denial grounds, and termination
The statute requires FDA to authorize importation within 60 days of receiving the importer’s paperwork, unless the agency exercises a discretionary denial. Denial grounds are narrowly enumerated: lack of safety/effectiveness, unsafe device coupling, or rescission of foreign authorization for safety reasons. The importation authority ends after three years or once the shortage is resolved. Those deadlines create predictable windows for market entry but also force FDA to make relatively rapid safety and supply assessments.
Marginally competitive market designation and consequences
The bill creates §506C–2 to let FDA declare that certain thin markets are ‘‘marginally competitive’’ and to treat them as shortages for the purposes of the shortage statute. When so designated, FDA may expedite ANDA reviews and inspections under the existing expedited review rules and is required to authorize importation under the new subsection. The policy design is to convert a persistent lack of adequate competitors into the same set of responses FDA uses for acute shortages.
How FDA determines marginal competition
The statute specifies three objective criteria: fewer than five commercially available referencing products for two consecutive months, the listed drug was approved at least 10 years ago, and all active‑ingredient patents have expired. It further defines commercially available to exclude discontinued or withdrawn products and gives FDA a ‘‘reasonable basis’’ standard to deem a product not competitively relevant; it also instructs FDA to count multiple approvals held by a single firm as one product for the headcount. These mechanics aim to target long‑standing, mature markets with concentrated supply.
Reporting addition: imported drug authorizations
The bill updates the required annual FDA shortage report to include the number of drugs authorized for temporary importation under the new authority. That creates a formal transparency metric so Congress, stakeholders, and the public can see how often FDA uses importation as a remedy.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Hospitals and health systems that face recurrent shortages of older, off‑patent drugs — they get a clear legal pathway to alternative supplies and a predictable 60‑day authorization clock that can relieve supply constraints.
- Patients and payers for whom imported alternatives may restore access or reduce price spikes in thin markets, because foreign products authorized for importation can increase immediate supply.
- Foreign manufacturers and U.S. importers that qualify — they gain a fast track to temporary U.S. market access tied to an ANDA filing commitment, potentially opening revenue opportunities in mature product lines.
- Generic applicants that can benefit from expedited FDA review and inspection if their product or market is designated marginally competitive, shortening time to approval.
Who Bears the Cost
- The FDA — it must perform faster reviews and inspections and evaluate foreign quality and safety claims within a compressed timetable, increasing agency workload without an appropriations mechanism in the bill.
- Brand and incumbent manufacturers in thin markets — they face potential price pressure and import competition even where patents have expired and they remain the primary supplier.
- Importers and foreign manufacturers — they assume regulatory and compliance risk (including proving product equivalence and safety) and must follow procedural attestations and potential follow‑on ANDA obligations.
- Supply chain managers for pharmacies and distributors — they must integrate foreign sources, track temporary authorizations, and manage potential transitions back to domestic products once importation authority ends.
Key Issues
The Core Tension
The central dilemma is between accelerating access and preserving regulatory and market safeguards: the bill speeds supply by allowing imports and faster ANDA processing in thin markets, but doing so risks undercutting safety oversight, complicating FDA workload, and potentially weakening incentives for domestic manufacturing and long‑term solutions to fragile supply chains.
The bill’s approach bundles two different remedies — expedited domestic generic entry and temporary importation — but leaves several operational questions unresolved. First, FDA must determine ‘‘commercially available’’ and ‘‘competitively relevant’’ with a flexible standard that invites judgment calls; how the agency applies that standard will materially affect how often markets are designated marginal.
The rule that multiple approvals held by a single entity count as one product is a blunt instrument: it recognizes the economic reality of tied portfolios but may undercount distinct sources that are operationally independent but corporate‑linked.
Second, tying importation to a manufacturer’s certification of intent to file an ANDA addresses the concern that importation would be a permanent substitute for domestic approval, but the bill lacks enforcement detail. What constitutes sufficient proof of intent or a binding commitment?
Similarly, the importer attestation and reliance on the §804(a) importer definition leave open questions about liability, inspection access, and ongoing compliance monitoring for foreign sites. The 60‑day authorization deadline presses FDA to balance rapid access against adequate inspection and verification; if FDA routinely denies within that window for safety reasons, stakeholders will still face supply gaps.
Finally, the bill does not address the interplay with exclusivities, REMS requirements, or other non‑patent regulatory barriers that can keep generics off the market despite patent expiry.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.